MX2024012446A - Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de mek - Google Patents
Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de mekInfo
- Publication number
- MX2024012446A MX2024012446A MX2024012446A MX2024012446A MX2024012446A MX 2024012446 A MX2024012446 A MX 2024012446A MX 2024012446 A MX2024012446 A MX 2024012446A MX 2024012446 A MX2024012446 A MX 2024012446A MX 2024012446 A MX2024012446 A MX 2024012446A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combination therapies
- sos1
- mek
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329104P | 2022-04-08 | 2022-04-08 | |
| PCT/US2023/017254 WO2023196218A2 (en) | 2022-04-08 | 2023-04-03 | Combination therapies comprising a sos1 inhibitor and a mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012446A true MX2024012446A (es) | 2024-11-08 |
Family
ID=88243402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012446A MX2024012446A (es) | 2022-04-08 | 2024-10-07 | Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de mek |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186453A1 (https=) |
| EP (1) | EP4504197A4 (https=) |
| JP (1) | JP2025513802A (https=) |
| KR (1) | KR20250002214A (https=) |
| CN (1) | CN118973580A (https=) |
| AU (1) | AU2023250314A1 (https=) |
| CA (2) | CA3245730A1 (https=) |
| IL (1) | IL315648A (https=) |
| MX (1) | MX2024012446A (https=) |
| WO (1) | WO2023196218A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558979B1 (en) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021263742A1 (en) * | 2020-04-27 | 2022-09-22 | Verastem, Inc. | Methods of treating abnormal cell growth |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| WO2022051568A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
| US12280055B2 (en) * | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3221608A1 (en) * | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
-
2023
- 2023-04-03 AU AU2023250314A patent/AU2023250314A1/en active Pending
- 2023-04-03 WO PCT/US2023/017254 patent/WO2023196218A2/en not_active Ceased
- 2023-04-03 KR KR1020247033661A patent/KR20250002214A/ko active Pending
- 2023-04-03 IL IL315648A patent/IL315648A/en unknown
- 2023-04-03 EP EP23785216.5A patent/EP4504197A4/en active Pending
- 2023-04-03 US US18/852,225 patent/US20250186453A1/en active Pending
- 2023-04-03 CA CA3245730A patent/CA3245730A1/en active Pending
- 2023-04-03 JP JP2024559468A patent/JP2025513802A/ja active Pending
- 2023-04-03 CN CN202380032771.6A patent/CN118973580A/zh active Pending
- 2023-04-03 CA CA3255758A patent/CA3255758A1/en active Pending
-
2024
- 2024-10-07 MX MX2024012446A patent/MX2024012446A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023196218A3 (en) | 2023-11-16 |
| JP2025513802A (ja) | 2025-04-30 |
| CA3255758A1 (en) | 2023-10-12 |
| IL315648A (en) | 2024-11-01 |
| US20250186453A1 (en) | 2025-06-12 |
| WO2023196218A2 (en) | 2023-10-12 |
| AU2023250314A1 (en) | 2024-10-03 |
| CA3245730A1 (en) | 2023-10-12 |
| CN118973580A (zh) | 2024-11-15 |
| KR20250002214A (ko) | 2025-01-07 |
| EP4504197A4 (en) | 2026-03-18 |
| EP4504197A2 (en) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004215A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1. | |
| MX2024012445A (es) | Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr | |
| MX2024009727A (es) | Terapias de combinacion. | |
| MX2024013525A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| MX2023002248A (es) | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| EP4011376A3 (en) | Combination of an alk inhibitor and an egfr inhibitor for treating cancer | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| MX2025015204A (es) | Metodos de uso de una composicion liposomal que comprende un inhibidor de atr | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| EP4589014A3 (en) | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden | |
| MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
| MX2024004214A (es) | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. | |
| MX2024012446A (es) | Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de mek | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| PH12022552347A1 (en) | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| MX2025013118A (es) | Tratamiento combinado para una enfermedad o un trastorno relacionado con ras | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer |